WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops novel
anticancer therapeutics using its antibody-drug conjugate (ADC)
technology, today announced the Company will participate in
the Canaccord Genuity 35th Annual Growth Conference.
ImmunoGen President and CEO Daniel Junius will discuss the Company in a
"fireside chat" moderated question and answer session that will be
webcast beginning at 1 pm ET on August 12, 2015.
This webcast will be accessible live through the "Investors" section of
the Company's website, www.immunogen.com;
a replay will be available at the same location for approximately a week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen
cell-killing agent specifically to cancer cells. The Company utilizes
its ADC technology with its antibodies to create ImmunoGen product
candidates and also out-licenses limited rights to use its technology to
other companies. Roche's Kadcyla® is the first marketed
product with ImmunoGen's ADC technology. More information about the
Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150810006018/en/
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com
or
For
Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
Source: ImmunoGen, Inc.
News Provided by Acquire Media